Cargando…
Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172421/ https://www.ncbi.nlm.nih.gov/pubmed/29717027 http://dx.doi.org/10.1042/BSR20180044 |
_version_ | 1783360945328750592 |
---|---|
author | Fu, Jun Li, Yanyan Li, Zhanzhan Li, Na |
author_facet | Fu, Jun Li, Yanyan Li, Zhanzhan Li, Na |
author_sort | Fu, Jun |
collection | PubMed |
description | We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang databases. The bivariate random-effect model was used to calculate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood, diagnostic odds ratio (DOR), and summary area under the curve (AUC). Fourteen studies were included in the meta-analysis. For decarboxylation prothrombin, the overall pooled parameters are as follows: sensitivity: 79% (95% confidence interval (CI): 74–84%), specificity: 91% (95%CI: 87–93%), PLR: 8.42 (95%CI: 5.79–12.23), negative likelihood ratio (NLR): 0.23 (95%CI: 0.17–0.30), DOR: 37.09 (95%CI: 21.37–64.36), summary AUC: 0.92 (95%CI: 0.89–0.94); for combined diagnostic, the overall pooled parameters were as follows: sensitivity: 91% (95%CI: 85–95%), specificity: 83% (95%CI: 74–89%), PLR: 5.26 (95%CI: 3.53–7.83), NLR: 0.11 (95%CI: 0.07–0.18), DOR: 47.14 (95%CI: 30.09–73.85), summary AUC: 0.94 (95%CI: 0.91–0.95). The serum decarboxylation prothrombin showed a relatively higher diagnostic specificity for primary HCC and decarboxylation prothrombin combined with AFP exhibited can improve sensitivity for HCC than any of the biomarkers alone. |
format | Online Article Text |
id | pubmed-6172421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61724212018-10-19 Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma Fu, Jun Li, Yanyan Li, Zhanzhan Li, Na Biosci Rep Research Articles We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang databases. The bivariate random-effect model was used to calculate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood, diagnostic odds ratio (DOR), and summary area under the curve (AUC). Fourteen studies were included in the meta-analysis. For decarboxylation prothrombin, the overall pooled parameters are as follows: sensitivity: 79% (95% confidence interval (CI): 74–84%), specificity: 91% (95%CI: 87–93%), PLR: 8.42 (95%CI: 5.79–12.23), negative likelihood ratio (NLR): 0.23 (95%CI: 0.17–0.30), DOR: 37.09 (95%CI: 21.37–64.36), summary AUC: 0.92 (95%CI: 0.89–0.94); for combined diagnostic, the overall pooled parameters were as follows: sensitivity: 91% (95%CI: 85–95%), specificity: 83% (95%CI: 74–89%), PLR: 5.26 (95%CI: 3.53–7.83), NLR: 0.11 (95%CI: 0.07–0.18), DOR: 47.14 (95%CI: 30.09–73.85), summary AUC: 0.94 (95%CI: 0.91–0.95). The serum decarboxylation prothrombin showed a relatively higher diagnostic specificity for primary HCC and decarboxylation prothrombin combined with AFP exhibited can improve sensitivity for HCC than any of the biomarkers alone. Portland Press Ltd. 2018-10-05 /pmc/articles/PMC6172421/ /pubmed/29717027 http://dx.doi.org/10.1042/BSR20180044 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Articles Fu, Jun Li, Yanyan Li, Zhanzhan Li, Na Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title | Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title_full | Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title_fullStr | Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title_full_unstemmed | Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title_short | Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
title_sort | clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172421/ https://www.ncbi.nlm.nih.gov/pubmed/29717027 http://dx.doi.org/10.1042/BSR20180044 |
work_keys_str_mv | AT fujun clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma AT liyanyan clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma AT lizhanzhan clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma AT lina clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma |